IONIZABLE LIPIDS FOR NANOMATERIALS

1 . A compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

L 1 is a covalent bond, —C(O)—, or —OC(O)—;

L 2 is a covalent bond, an optionally substituted bivalent saturated or unsaturated, straight or branched C 1 -C 12 hydrocarbon chain, or

Cy A is an optionally substituted ring selected from phenylene and 3- to 7-membered saturated or partially unsaturated carbocyclene;

each m is independently 0, 1, or 2;

L 3 is a covalent bond, —C(O)—, —C(O)O—, —OC(O)—, —O—, or —OC(O)O—;

R 1 is

or an optionally substituted saturated or unsaturated, straight or branched C

1 -C 20 hydrocarbon chain wherein 1-3 methylene units are optionally and independently replaced with —O— or -NR-;

Cy B is an optionally substituted ring selected from 3- to 12-membered saturated or partially unsaturated carbocyclyl, 1-adamantyl, 2-adamantyl,

sterolyl, and phenyl;

p is 0, 1, 2, or 3;

X 1 is a covalent bond, —O—, or -NR-;

X 2 is a covalent bond or an optionally substituted, bivalent saturated or unsaturated, straight or branched, C 1 -C 12 hydrocarbon chain, wherein 1-3 methylene units are optionally and independently replaced with —O—, -NR-, or —Cy C —;

Cy C is an optionally substituted ring selected from 3- to 7- membered saturated or partially unsaturated carbocyclene, phenylene, 3- to 7-membered saturated or partially unsaturated heterocyclene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

X 3 is hydrogen or an optionally substituted ring selected from 3- to 7-membered saturated or partially unsaturated carbocyclyl, phenyl, 3- to 7-membered saturated or partially unsaturated heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

each R is independently hydrogen or an optionally substituted C 1 -C 6 aliphatic group;

Z 1 is a covalent bond or —O—;

Z 2 is an optionally substituted group selected from 4- to 12-membered saturated or partially unsaturated carbocyclyl, phenyl, 1-adamantyl, and 2-adamantyl;

Z 3 is hydrogen, or an optionally substituted group selected from C 1 -C 10 aliphatic, and 4- to 12-membered saturated or partially unsaturated carbocyclyl; and

d is 0, 1, 2, 3, 4, 5, or 6;

provided that when L 3 is a covalent bond, then R 1 must be

.

2 . The compound of claim 1 , wherein the compound is of Formula (II):

or a pharmaceutically acceptable salt thereof.

3 . The compound of claim 1 , wherein the compound is of Formula (III):

or a pharmaceutically acceptable salt thereof.

4 . The compound of claim 1 , wherein the compound is of Formula (IIIA):

or a pharmaceutically acceptable salt thereof.

5 . (canceled)

6 . The compound of claim 1 , wherein the compound is of Formula (IV):

or a pharmaceutically acceptable salt thereof.

7 . (canceled)

8 . The compound of claim 1 , wherein the compound is of Formula (V):

or a pharmaceutically acceptable salt thereof.

9 - 10 . (canceled)

11 . The compound of claim 1 , wherein L 2 is an optionally substituted bivalent saturated or unsaturated, straight or branched C 1 -C 12 hydrocarbon chain.

12 . The compound of claim 1 , wherein L 3 is —C(O)O—.

13 . The compound of claim 1 , wherein L 3 is —OC(O)—.

14 . The compound of claim 1 , wherein R 1 is

.

15 . (canceled)

16 . The compound of claim 1 , wherein R 1 is a saturated or unsaturated, straight or branched C 6 -C 20 hydrocarbon chain optionally substituted with 1-6 fluorine atoms.

17 . The compound of claim 1 , wherein R 1 is selected from:

.

18 . (canceled)

19 . The compound of claim 1 , wherein X 2 is an optionally substituted, bivalent saturated or unsaturated, straight or branched, C 1 -C 12 hydrocarbon chain, wherein 1-3 methylene units are optionally and independently replaced with —O—, -NR-, or —Cy C —.

20 . The compound of claim 1 , wherein -X 2 -X 3 is selected from:

.

21 . The compound of claim 1 , wherein Z 1 is a covalent bond.

22 . The compound of claim 1 , wherein Z 2 is optionally substituted 4- to 12-membered saturated or partially unsaturated carbocyclyl.

23 . (canceled)

24 . A compound selected from:

or a pharmaceutically acceptable salt thereof.

25 . A lipid nanoparticle (LNP) preparation comprising an ionizable lipid, wherein the ionizable lipid is a compound according to claim 1 .

26 . A lipid nanoparticle (LNP) preparation comprising an ionizable lipid, wherein the ionizable lipid is a compound according to claim 24 .

27 - 33 . (canceled)

34 . A pharmaceutical composition comprising a LNP preparation of claim 25 and a pharmaceutically acceptable excipient.

35 . A method for administering a therapeutic and/or prophylactic agent to a subject in need thereof, the method comprising administering the LNP preparation of claim 25 to the subject.

36 . A method for treating a disease or a disorder in a subject in need thereof, the method comprising administering the LNP preparation of claim 25 to the subject, wherein the therapeutic and/or prophylactic agent is effective to treat the disease.

37 . (canceled)

38 . A method of delivering a therapeutic and/or prophylactic agent to a mammalian cell derived from a subject, the method comprising contacting the cell of the subject having been administered the LNP preparation of claim 25 .

39 . A method of producing a polypeptide of interest in a mammalian cell, the method comprising contacting the cell with the LNP preparation of claim 25 , wherein the therapeutic and/or prophylactic agent is or comprises an mRNA, and wherein the mRNA encodes the polypeptide of interest, whereby the mRNA is capable of being translated in the cell to produce the polypeptide of interest.

40 . A method of inhibiting production of a polypeptide of interest in a mammalian cell, the method comprising contacting the cell with the LNP preparation of claim 25 , wherein the therapeutic and/or prophylactic agent is or comprises an RNA, whereby the RNA is capable of inhibiting production of the polypeptide of interest.

41 . A method of specifically delivering a therapeutic and/or prophylactic agent to a mammalian organ, the method comprising contacting a mammalian organ with the LNP preparation of claim 25 , whereby the therapeutic and/or prophylactic agent is delivered to the organ.

42 - 44 . (canceled)